StimCardio closes oversubscribed $30 million Series A financing led by Metis Medtech to advance their wearable therapeutic for atrial fibrillation.
PRIVATEOct 29, 2026
Amount Raised
$30 Million
Round Type
Series A
Los AngelesBiotechnologyHealth CareMedicalMedical DeviceTherapeutics
Investors
Catalyst Health VenturesMetis Medtech
Description
StimCardio, a clinical-stage medical device company, has closed an oversubscribed $30 million Series A financing. The funding, led by John Slump's family office, Metis Medtech, will support a pivotal trial for their investigational therapy Rhyvive™. This investment also aids in the preparation for a De Novo submission to the FDA. The company aims to innovate cardiac treatment beyond conventional methods.
Who to call at StimCardio, and when
A new round usually means StimCardio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day StimCardio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at StimCardio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at StimCardio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
StimCardio
Location
Los Angeles, California, United States
About
StimCardio is a clinical-stage medical device company developing non-invasive wearable therapeutics for atrial fibrillation (AF). Their lead product, Rhyvive, is designed to extend AF treatment into the home by using personalized, non-invasive median nerve stimulation. StimCardio aims to establish a new therapeutic category in cardiac electrophysiology with their innovative technology. The company is committed to addressing significant clinical challenges related to AF recurrence.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment StimCardio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Los AngelesBiotechnologyHealth CareMedicalMedical DeviceTherapeutics